Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer : A clinician's guide to statistical methods in urologic oncologyHALABI, Susan.Urologic oncology. 2008, Vol 26, Num 3, pp 300-307, issn 1078-1439, 8 p.Article

Flexible Frames and Control Sampling in Case-Control Studies : Weighters (Survey Statisticians) Versus Anti-Weighters (Epidemiologists)POTTHOFF, Richard F; HALABI, Susan; SCHILDKRAUT, Joellen M et al.The American statistician. 2008, Vol 62, Num 4, pp 307-313, issn 0003-1305, 7 p.Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancerHALABI, Susan; OU, San-San; VOGELZANG, Nicholas J et al.Cancer. 2007, Vol 110, Num 7, pp 1478-1484, issn 0008-543X, 7 p.Article

The impact of Prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: A pooled analysis of 9 Cancer and Leukemia Group B trialsHALABI, Susan; VOGELZANG, Nicholas J; OU, San-San et al.The Journal of urology. 2007, Vol 177, Num 2, pp 531-534, issn 0022-5347, 4 p.Article

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate CancerHALABI, Susan; LIN, Chen-Yen; KELLY, W. Kevin et al.Journal of clinical oncology. 2014, Vol 32, Num 7, pp 671-677, issn 0732-183X, 7 p.Article

Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate CancerHALABI, Susan; VOGELZANG, Nicholas J; OU, San-San et al.Journal of clinical oncology. 2009, Vol 27, Num 17, pp 2766-2771, issn 0732-183X, 6 p.Article

Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal WomenMOORMAN, Patricia G; CALINGAERT, Brian; PALMIERI, Rachel T et al.American journal of epidemiology. 2008, Vol 167, Num 9, pp 1059-1069, issn 0002-9262, 11 p.Article

Activities and accomplishments of the cancer and leukemia Group B genitourinary committeeSMALL, Eric J; HALABI, Susan; KANTOFF, Phillip et al.Clinical cancer research. 2006, Vol 12, Num 11, issn 1078-0432, 3596s-3600s, 2Article

The prognostic significance of Plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480GEORGE, Daniel J; HALABI, Susan; SHEPARD, Timothy F et al.Clinical cancer research. 2005, Vol 11, Num 5, pp 1815-1820, issn 1078-0432, 6 p.Article

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working groupSCHER, Howard I; EISENBERGER, Mario; CARDUCCI, Michael A et al.Journal of clinical oncology. 2004, Vol 22, Num 3, pp 537-556, issn 0732-183X, 20 p.Article

Impact of race on survival in men with metastatic hormone-refractory prostate cancerHALABI, Susan; SMALL, Eric J; VOGELZANG, Nicholas J et al.Urology (Ridgewood, NJ). 2004, Vol 64, Num 2, pp 212-217, issn 0090-4295, 6 p.Article

Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial CancerTreated With Cisplatin-Based ChemotherapyAPOLO, Andrea B; OSTROVNAYA, Irina; HALABI, Susan et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 7, pp 499-503, issn 0027-8874, 5 p.Article

Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosi, BoliviaHAGAN, Nicole; ROBINS, Nicholas; HSU-KIM, Heileen et al.Atmospheric environment (1994). 2011, Vol 45, Num 40, pp 7619-7626, issn 1352-2310, 8 p.Conference Paper

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerGULLEY, James L; ARLEN, Philip M; CEREDA, Vittore et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 5, pp 663-674, issn 0340-7004, 12 p.Article

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a cancer and leukemia group B studyRYAN, Charles J; HALABI, Susan; OU, San-San et al.Clinical cancer research. 2007, Vol 13, Num 7, pp 2030-2037, issn 1078-0432, 8 p.Article

Age at natural menopause and the risk of epithelial ovarian cancerSCHILDKRAUT, Joellen M; COOPER, Glinda S; HALABI, Susan et al.Obstetrics and gynecology (New York. 1953). 2001, Vol 98, Num 1, pp 85-90, issn 0029-7844Article

Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quitMCBRIDE, Colleen M; HALABI, Susan; BEPLER, Gerold et al.Journal of health communication. 2000, Vol 5, Num 3, pp 229-241, issn 1081-0730Article

Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell CarcinomaHALABI, Susan; RINI, Brian; ESCUDIER, Bernard et al.Cancer. 2014, Vol 120, Num 1, pp 52-60, issn 0008-543X, 9 p.Article

Antidepressant medication use for and risk of ovarian cancerMOORMAN, Patricia G; BERCHUCK, Andrew; CALINGAERT, Brian et al.Obstetrics and gynecology (New York. 1953). 2005, Vol 105, Num 4, pp 725-730, issn 0029-7844, 6 p.Article

Menopausal hormones and risk of ovarian cancerMOORMAN, Patricia G; SCHILDKRAUT, Joellen M; CALINGAERT, Brian et al.American journal of obstetrics and gynecology. 2005, Vol 193, Num 1, pp 76-82, issn 0002-9378, 7 p.Article

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583HALABI, Susan; SMALL, Eric J; HAYES, Daniel F et al.Journal of clinical oncology. 2003, Vol 21, Num 3, pp 490-495, issn 0732-183X, 6 p.Article

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer: Results From a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)AGGARWAL, Rahul; HALABI, Susan; CARDUCCI, Michael et al.Cancer. 2013, Vol 119, Num 20, pp 3636-3643, issn 0008-543X, 8 p.Article

Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line ChemotherapyHALABI, Susan; LIN, Chen-Yen; SARTOR, Oliver et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 22, pp 1729-1737, issn 0027-8874, 9 p.Article

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206RINI, Brian I; HALABI, Susan; SMALL, Eric J et al.Journal of clinical oncology. 2010, Vol 28, Num 13, pp 2137-2143, issn 0732-183X, 7 p.Article